872
Participants
Start Date
October 7, 2014
Primary Completion Date
December 25, 2015
Study Completion Date
May 24, 2016
Ustekinumab
45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
Guselkumab
100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
Placebo for ustekinumab
Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
Placebo for guselkumab
Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
Birmingham
Bakersfield
Los Angeles
Santa Monica
Coral Gables
Ocala
Alpharetta
Atlanta
Arlington Heights
Chicago
Skokie
Indianapolis
Plainfield
Louisville
Boston
Troy
Buffalo
New York
Portland
Pittsburgh
Johnston
Nashville
Arlington
Austin
Dallas
San Antonio
Webster
Norfolk
Spokane
Fremantle
Victoria Park
Woden
Woolloongabba
Surrey
Vancouver
Moncton
Halifax
Ajax
Richmond Hill
Montreal
Québec
Berlin
Bonn
Essen
Gera
Hamburg
Leipzig
Lübeck
Mahlow
Münster
Witten
Bialystok
Bydgoszcz
Gdansk
Krakow
Lodz
Lublin
Olsztyn
Poznan
Torun
Warsaw
Wroclaw
Chelyabinsk
Krasnodar
Lipetsk
Saint Petersburg
Stavropol
Ufa
Yekaterinburg
Anyang
Incheon
Seoul
A Coruña
Alcorcón
Alicante
Barcelona
Madrid
Taichung
Tainan City
Taipei
Taoyuan District
Dudley
Dundee
London
Salford
Janssen Research & Development, LLC
INDUSTRY